Mepromax Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 8.50 M
as on 16-11-2024
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.37 Cr
as on 16-11-2024
- Satisfied Charges ₹ 12.30 Cr
as on 16-11-2024
- Revenue -2.97%
(FY 2023)
- Profit -384.18%
(FY 2023)
- Ebitda -303.35%
(FY 2023)
- Net Worth -11.67%
(FY 2023)
- Total Assets -7.68%
(FY 2023)
About Mepromax Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.50 M.
The company currently has active open charges totaling ₹6.37 Cr. The company has closed loans amounting to ₹12.30 Cr, as per Ministry of Corporate Affairs (MCA) records.
Suresh Shah, Prakash Shah, Rajesh Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231GJ2005PTC045918
- Company No.
045918
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Apr 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surendra Nagar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Mepromax Life Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Shah  | Whole-Time Director | 15-Jun-2006 | Current |
| Suresh Shah | Whole-Time Director | 15-Jun-2006 | Current |
| Prakash Shah | Whole-Time Director | 15-Jun-2006 | Current |
| Bharatkumar Shah | Whole-Time Director | 15-Jun-2006 | Current |
Financial Performance of Mepromax Life Sciences.
Mepromax Life Sciences Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.97% decrease. The company also saw a substantial fall in profitability, with a 384.18% decrease in profit. The company's net worth observed a substantial decline by a decrease of 11.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mepromax Life Sciences?
In 2023, Mepromax Life Sciences had a promoter holding of 48.33% and a public holding of 51.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sunshine Organics Pvt LtdActive 36 years 2 monthsRajesh Shah and Bharatkumar Shah are mutual person
Mepro Pharmaceuticals Private LimitedActive 42 years 3 monthsSuresh Shah, Prakash Shah and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Sep 2007 | ₹6.37 Cr | Open |
Icici Bank Limited Creation Date: 19 Jan 2007 | ₹6.15 Cr | Satisfied |
Icici Bank Limited Creation Date: 31 Jul 2006 | ₹6.15 Cr | Satisfied |
How Many Employees Work at Mepromax Life Sciences?
Mepromax Life Sciences has a workforce of 71 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mepromax Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mepromax Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
